Health Catalyst, Inc. (HCAT) — Analyst outlook / Analyst consensus target is. Based on 22 analyst ratings, the consensus is bullish — 12 Buy, 10 Hold.
The consensus price target is $3.00 (low: $2.00, high: $4.00), representing an upside of 167.9% from the current price $1.12.
Analysts estimate Earnings Per Share (EPS) of $0.31 and revenue of $0.31B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.15 vs est $0.31 (missed -468.2%). 2025: actual $-2.55 vs est $0.20 (missed -1378.1%). Analyst accuracy: 0%.
HCAT Stock — 12-Month Price Forecast
$3.00
▲ +167.86% Upside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for Health Catalyst, Inc., the average price target is $3.00, with a high forecast of $4.00, and a low forecast of $2.00.
The average price target represents a +167.86% change from the last price of $1.12.
Highest Price Target
$4.00
Average Price Target
$3.00
Lowest Price Target
$2.00
HCAT Analyst Ratings
Buy
Based on 22 analysts giving stock ratings to Health Catalyst, Inc. in the past 3 months
EPS Estimates — HCAT
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.15
vs Est $0.31
▼ 127.2% off
2025
Actual –$2.55
vs Est $0.20
▼ 107.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect the company to turn profitable.
Revenue Estimates — HCAT
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.307B
vs Est $0.307B
▲ 0.0% off
2025
Actual $0.311B
vs Est $0.310B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
